期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 467, 期 1-2, 页码 100-112出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2014.03.049
关键词
Chitosan lactate; Na tripolyphosphate; Buccoadhesive; Wafer containing; beads; Central composite face-centered design
Tizanidine HCl is a skeletal muscle relaxant that suffers from extensive hepatic metabolism resulting in 34-40% oral bioavailability. It also suffers from short half-life (2.1-4.2 h) that necessitates frequent administration thus reducing patient compliance. In addition, tizanidine HCl is water soluble, so it is a challenging candidate for controlled drug delivery. In our study, tizanidine was encapsulated in chitosan lactate beads cross-linked with sodium tripolyphosphate. The beads were further incorporated into chitosan lactate wafer to be easily applied to buccal mucosa, aiming to bypass the hepatic metabolism. A central composite face-centered design was applied to statistically optimize the formulation variables; tripolyphosphate concentration, chitosan lactate concentration and polymer/drug ratio. The optimized formula suggested by the software composed of; 3.03% tripolyphosphate, 4.92% chitosan lactate and 2.13 polymer/drug ratio. It provided encapsulation efficiency of 56.5% and controlled tizanidine release over 8 h. It is also characterized by being mucoadhesive and nonirritant. Pharmacokinetic parameters of tizanidine from the optimized formula were compared to those of the immediate release tablet, Sirdalud (R), as reference in human volunteers using a randomized crossover design. Significant increase was observed for T-max and AUC((0-infinity)). The increase in relative bioavailability of TIZ from the optimized formula was 2.27 fold. (C) 2014 Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据